✦ LIBER ✦

The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors

✍ Scribed by E. D. GOMPERTS

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rate of inhibitor development in previou

✍ A. IORIO; S. HALIMEH; S. HOLZHAUER; N. GOLDENBERG; E. MARCHESINI; M. MARCUCCI; G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB

Treatment characteristics and the risk o

✍ S. C. GOUW; H. M. VAN DEN BERG; S. LE CESSIE; J. G. VAN DER BOM 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 503 KB

The prevalence of factor VIII inhibitors

✍ X. F. WANG; Y. Q. ZHAO; R. C. YANG; J. S. WU; J. SUN; X. S. ZHANG; Q. L. DING; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

A prospective surveillance study of fact

✍ M. RUBINGER; D. LILLICRAP; G. E. RIVARD; J. TEITEL; M. CARCAO; C. HENSMAN; I. WA 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

Factor VIII products and inhibitor devel

✍ P. M. MANNUCCI; A. GRINGERI; F. PEYVANDI; E. SANTAGOSTINO 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

Low incidence of factor VIII inhibitors

✍ A. KLUKOWSKA; V. KOMRSKA; M. JANSEN; P. LAGUNA 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB